Metagenomi Therapeutics Inc (MGX) FinancialsMGXMetagenomi Therapeutics Inc

Evaluating the bottom line, Metagenomi Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5384.46%, while the net margin is -5100.00%. These profitability ratios, combined with a Return on Equity (ROE) of -60.61%, provide a clear picture of how effectively MGX converts its operational activities into shareholder value.

In the context of the broader market, MGX competes directly with industry leaders such as VERU and GRCE. With a market capitalization of $44.58M, it holds a significant position in the sector. When comparing efficiency, MGX's gross margin of 100.00% stands against VERU's N/A and GRCE's N/A. Such benchmarking helps identify whether Metagenomi Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Metagenomi has reported substantial net losses, with a net income of -$27,482,000 in Q2 2026 and a gross margin consistently at 100%. However, the company has seen a decline in collaboration revenue, down 69.7% year-over-year in Q1 2026.